Sorrento Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on the development of innovative therapies for cancer and autoimmune diseases. Founded in 2006, Sorrento has made significant strides in the biotechnology sector, particularly in the fields of immunotherapy and antibody development. The company is renowned for its proprietary antibody platform, which includes unique products such as the COVID-19 therapeutic candidate, COVI-MSC, and various cancer treatment modalities. Sorrento's commitment to advancing healthcare solutions has positioned it as a notable player in the biopharmaceutical industry, with a robust pipeline aimed at addressing unmet medical needs. With operations extending across major regions, Sorrento Therapeutics continues to drive innovation and improve patient outcomes globally.
How does Sorrento Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sorrento Therapeutics, Inc.'s score of 25 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sorrento Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Sorrento Therapeutics may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the company does not inherit emissions data from a parent organisation, it operates independently regarding its climate impact reporting. Without available emissions data or reduction initiatives, Sorrento Therapeutics remains in a position where it could potentially enhance its environmental strategy by setting measurable targets and participating in recognised climate frameworks.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sorrento Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.